Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) - Phase I Evaluation of the Integration and Safety of the HeartLogic Multisensor Algorithm in Patients With Heart Failure

Background: Patients with heart failure (HF) and reduced ejection fraction suffer from a relapsing and remitting disease course, where early treatment changes may improve outcomes. We assessed the clinical integration and safety of the HeartLogic multisensor index and alerts in HF care. Methods: The Multiple cArdiac seNsors for mAnaGEment of Heart Failure (MANAGE-HF) study enrolled 200 patients with HF and reduced ejection fraction (< 35%), New York Heart Association functional class II -III symptoms, implanted with a cardiac resynchronization therapy-defibrillator or and implantable cardioverter defibrillator, who had either a hospitalization for HF within 12 months or unscheduled visit for HF exacerbation within 90 days or an elevated natri-uretic peptide concentration (brain natriuretic peptide [BNP] of >= 150 pg/mL or N-terminal pro-BNP [NT-proBNP] of >= 600 pg/mL). This phase included the development of an alert management guide and evaluated changes in medical treatment, natriuretic peptide levels, and safety. Results: The mean age of participants was 67 years, 68% were men, 81% were White, and 61% had a HF hospitalization in prior 12 months. During follow-up, there were 585 alert cases with an average of 1.76 alert cases per patient-year. HF medications were augmented during 74% of the alert cases. HF treatment augmentation within 2 weeks from an initial alert was associated with more rapid recovery of the HeartLogic Index. Five serious adverse events (0.015 per patient-year) occurred in relation to alert-prompted medication change. NTproBNP levels decreased from median of 1316 pg/mL at baseline to 743 pg/mL at 12 months (P < .001). Conclusions: HeartLogic alert management was safely implemented in HF care and may optimize HF management. This phase supports further evaluation in larger studies. Trial Registration: ClinicalTrials.gov (NCT03237858) (J Cardiac Fail 2022;28:1245-1254)

Automated summary

The clinical integration and safety of the HeartLogic multisensor index and alerts in heart failure (HF) care were evaluated. The study found that alert cases prompted augmentation of HF medications and were associated with faster recovery of the HeartLogic Index. Although there were a few serious adverse events related to alert-prompted medication change, the overall implementation of HeartLogic alert management was deemed safe in HF care. The levels of NTproBNP significantly decreased during the treatment process.